This study presents an innovative bifunctional design to address insufficient CAR-T cell infiltration and the immunosuppressive microenvironment in solid tumors, offering direct guidance for optimizing CAR-T therapies.
Literature Overview
The article titled "Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment," published in the Journal of Hematology & Oncology, systematically explores the application of a CAR-T cell platform that targets cancer-associated fibroblasts (CAFs) and locally releases anti-CTLA-4 nanobodies for solid tumor therapy. By constructing FAP/CTLA-4-DMN CAR-T cells, this approach aims to simultaneously eliminate stromal barriers and alleviate Treg-mediated immunosuppression, thereby reshaping the tumor immune microenvironment. This strategy not only enhances T cell persistence and functionality but also demonstrates disease stabilization and favorable safety in a treatment-refractory glioblastoma patient.Background Knowledge
Solid tumor therapy has long been hindered by antigen heterogeneity and a highly immunosuppressive tumor microenvironment (TME), making it difficult to replicate the success of CAR-T therapy observed in hematological malignancies. Cancer-associated fibroblasts (CAFs), as a core component of the TME, highly express FAP and contribute to the formation of dense physical barriers while secreting immunosuppressive factors such as TGF-β and CXCL12 that inhibit T cell function. Meanwhile, the immune checkpoint CTLA-4 is highly expressed on regulatory T cells (Tregs) and plays a key role in suppressing anti-tumor immunity. However, systemic use of CTLA-4 antibodies often causes severe immune-related adverse events (irAEs), limiting their clinical utility. Therefore, effectively blocking CTLA-4 without inducing systemic toxicity remains a major research challenge. This study's innovation lies in using CAR-T cells as "living drugs" that target FAP-positive CAFs while locally secreting anti-CTLA-4 nanobodies, enabling dual immune modulation—disrupting stromal barriers and activating endogenous T cells—to overcome the dual resistance mechanisms of solid tumors.
Research Methods and Experiments
The authors developed a nanobody-based FAP/CTLA-4-DMN CAR-T cell system, in which the CAR targets FAP and the T cells are engineered to secrete anti-CTLA-4 nanobodies. This system employs a lentiviral vector to co-express the FAP-CAR and a secreted anti-CTLA-4 nanobody via an IRES linker. In vitro, the specificity and cytotoxic capacity of the CAR-T cells were validated using FAP-positive cell lines such as HepG2-FAP and U87, along with cytokine secretion assays. Long-term co-culture experiments revealed that FAP/CTLA-4-DMN CAR-T cells exhibited lower expression of exhaustion markers including PD-1, LAG-3, and TIM-3, indicating enhanced resistance to T cell exhaustion.
In vivo, NOD/SCID mice bearing HepG2-FAP, U87, or patient-derived xenograft (PDX) models were used to evaluate anti-tumor efficacy. Results showed that FAP/CTLA-4-DMN CAR-T cells significantly suppressed tumor growth, prolonged survival, and demonstrated strong intratumoral retention in PDX models. Safety assessments revealed no significant organ toxicity or signs of cytokine release syndrome (CRS), with serum IL-6 levels lower than those in control groups.
In a clinical case, a patient with recurrent glioblastoma received intrathecal infusion of FAP/CTLA-4-DMN CAR-T cells. Following treatment, the patient achieved disease stability for over two years, with marked increases in IL-6 and IFN-γ levels in cerebrospinal fluid, indicating T cell activation, and no grade ≥3 adverse events or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed.Key Conclusions and Perspectives
Research Significance and Prospects
This study presents a novel paradigm for CAR-T therapy in solid tumors by integrating stromal targeting with localized immune checkpoint blockade, effectively addressing the dual challenges of poor T cell infiltration and functional suppression. The dual-module design is adaptable to other stromal targets or immune regulatory molecules, paving the way for next-generation CAR-T development.
From a drug development perspective, this platform enables "precision immune modulation," avoiding the toxicities associated with systemic CTLA-4 blockade and providing a template for designing combination immunotherapies. Future studies should validate these findings in larger cohorts and explore applications in other FAP-high tumors such as pancreatic and gastric cancers.
Conclusion
The FAP/CTLA-4-DMN CAR-T platform developed in this study represents a significant advance in immunotherapy for solid tumors. By simultaneously targeting cancer-associated fibroblasts and locally blocking CTLA-4, this strategy effectively remodels the immunosuppressive microenvironment, enhances T cell infiltration and function, and has demonstrated durable disease control in a treatment-refractory glioblastoma patient. Its innovative "dual-module" design not only improves the anti-tumor potency of CAR-T cells but also significantly enhances safety by avoiding the systemic toxicity associated with conventional CTLA-4 antibodies. This work provides a replicable technical pathway to overcome key barriers in solid tumor therapy and holds promise for extending CAR-T applications from hematological to solid malignancies. Future research should focus on expanding clinical trial cohorts, optimizing delivery routes, and exploring synergistic effects with other immunotherapies to achieve more effective interventions for refractory tumors such as glioblastoma. This study lays a solid foundation for developing smarter, safer "living drugs," marking a critical step toward a new era of personalized cell therapy.
